What are JAK inhibitors and how do they work? - Drugs.com
网页2023年10月26日 · Janus kinase (JAK) inhibitors are a group of medicines that help block immune system signals in the body that can lead to swelling (inflammation) and pain in conditions like rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis.
List of the 9 Leading JAK Inhibitor Drugs - GoodRx
网页2024年8月13日 · JAK inhibitors like Xeljanz, Rinvoq, and Opzelura can treat inflammatory conditions and even alopecia. View this list of JAK inhibitors to learn about their various uses.
JAK Inhibitors: Uses, Types, Side Effects, and More - Verywell Health
网页2024年2月5日 · Janus kinase (JAK) inhibitors are a group of medications that can treat various types of arthritis, including rheumatoid arthritis (RA), cancer, dermatological conditions like atopic dermatitis and alopecia areata, and some bowel conditions like ulcerative colitis and inflammatory bowel disease.
Which JAK inhibitors are approved in the U.S? - Drugs.com
网页2023年12月6日 · There are currently 10 Janus kinase (JAK) inhibitors approved by the U.S. Food and Drug Administration (FDA). The most recent JAK approval was Ojjaara (momelotinib) on September 15, 2023. The first JAK inhibitor approved in the U.S. was Jakafi (ruxolitinib) on Nov. 16, 2011.
Janus kinase inhibitor - Wikipedia
网页A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
A Comprehensive Overview of Globally Approved JAK Inhibitors
网页2022年5月6日 · In the current review, we aimed to provide an integrated overview of the chemical and pharmacological data of the globally approved JAK inhibitors that were approved for the treatment of inflammatory, autoimmune, and myeloproliferative diseases.
JAK inhibitor selectivity: new opportunities, better drugs?
网页2024年9月9日 · The first JAK inhibitor, ruxolitinib, was approved by the FDA in 2011, followed by tofacitinib in 2012 (refs. 17, 18). Since then, a dozen JAK inhibitors have been approved, providing additional ...
JAK Inhibitors for Rheumatoid Arthritis - WebMD
网页2023年9月13日 · 3 min read. If you have rheumatoid arthritis (RA), your doctor may suggest Janus kinase (JAK) inhibitors to help ease your joint pain and swelling. These drugs tamp down your overactive immune...
A Comprehensive Overview of Globally Approved JAK Inhibitors
网页2022年5月6日 · In the current review, eleven of the JAK inhibitors that received approval for clinical use have been discussed. These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib.
JAK inhibitors: new indication and emerging safety data in 2022
网页2022年12月19日 · Janus kinase (JAK) inhibitors have had a dramatic uptake across specialties, particularly in the management of autoimmune inflammatory rheumatic diseases.